Keyphrases
Asthma
6%
Bacterial Infection
5%
Birth Cohort Study
5%
Bronchiolitis
12%
Children with Down Syndrome
9%
Confidence Interval
6%
Disease Burden
5%
Disease Severity
14%
Down Syndrome
9%
First Year of Life
6%
Gestational Age
6%
Healthy children
5%
Hospitalization
9%
Immune Response
7%
Infections in children
5%
Inhibitory Receptors
6%
Innate Immune Response
5%
Interleukin-10
8%
Leukocytes
7%
Lower Respiratory Tract Infection
28%
Mechanical Ventilation
5%
Monoclonal Antibody
5%
Neonate
5%
Netherlands
10%
Palivizumab
9%
Polymorphism
5%
Preterm Infants
12%
Randomized Placebo-controlled Trial
5%
Recurrent Wheeze
7%
Recurrent Wheezing
8%
Respiratory Infection
9%
Respiratory Syncytial Virus
100%
Respiratory Syncytial Virus Bronchiolitis
36%
Respiratory Syncytial Virus Hospitalization
5%
Respiratory Syncytial Virus Infection
56%
Respiratory Syncytial Virus Vaccines
5%
Risk Factors
6%
Single nucleotide Polymorphism
7%
Strength of Evidence
5%
Toll-like
6%
Viral
5%
Viral Infection
7%
Viral Respiratory Infections
5%
Virus
6%
Virus Diseases
9%
Wheezing
21%
Young children
6%
Immunology and Microbiology
Asthma
10%
Bronchiolitis
36%
Cytokine
5%
Human Immunodeficiency Virus
7%
Human Respiratory Syncytial Virus
95%
Immune Response
8%
Infancy
6%
Infectious Agent
8%
Innate Immune System
7%
Interleukin 10
6%
Intravenous Immunoglobulin
5%
Leukocyte
7%
Lower Respiratory Tract
22%
Mouse
5%
Neutrophil Granulocyte
5%
Palivizumab
7%
Respiratory Syncytial Virus
9%
Respiratory Syncytial Virus Infection
45%
Single Nucleotide Polymorphism
5%
Vaccine Efficacy
5%
Viral Disease
8%
Medicine and Dentistry
Amnion Fluid
5%
Antibiotics
5%
Asthma
6%
Bronchiolitis
21%
Childbirth
7%
Cohort Analysis
5%
Disease
10%
Human Immunodeficiency Virus
5%
Human Respiratory Syncytial Virus
57%
Infection
8%
Lower Respiratory Tract Infection
16%
Palivizumab
5%
Placebo
5%
Respiratory Disease
6%
Respiratory Syncytial Virus
9%
Respiratory Syncytial Virus Infection
25%
Respiratory Tract Infection
11%
Toddlers
7%
Virus Infection
7%
Wheeze
28%
